Ovarian cancer's brutal lethality — it remains the most fatal gynecological malignancy — stems partly from a biological feedback loop that conventional treatments barely address: the senescence-associated secretory phenotype, or SASP. For the millions of women diagnosed after age 65, understanding how aging biology fuels tumor progression may reframe how researchers approach treatment resistance and immune evasion.
This review in Inflammopharmacology maps how cellular senescence, triggered by genomic instability, telomere attrition, mitochondrial dysfunction, and oxidative stress, activates SASP — a dense secretome of pro-inflammatory cytokines, chemokines, matrix-remodeling enzymes, and growth factors. Within ovarian tumors, SASP signaling drives epithelial-to-mesenchymal transition, promotes angiogenesis, and critically reprograms immune cells toward immunosuppression, creating conditions where both checkpoint inhibitors and PARP inhibitors lose efficacy. The review then catalogs phytochemicals and bioactive secondary metabolites — including flavonoids, polyphenols, and terpenoids — that demonstrate senolytic or senomorphic activity, capable of either clearing senescent cells or dampening their secretory output to disrupt these resistance pathways.
This analysis sits at a productive intersection of geroscience and oncology, a convergence that has accelerated following the senolytic trials using dasatinib and quercetin in humans. Importantly, SASP modulation as an anti-cancer strategy is mechanistically distinct from cytotoxicity: rather than killing tumor cells directly, it aims to normalize the tumor microenvironment. That distinction matters for therapeutic design. The limitations here are real, however — this is a narrative review, not a meta-analysis or clinical trial synthesis, and most cited phytochemical data derive from in vitro or animal models. Translation to human ovarian cancer pharmacology remains distant. Still, by framing natural compounds explicitly within cytokine-network and immune-evasion mechanisms, the review moves beyond generic antioxidant narratives and offers a more actionable mechanistic vocabulary for future drug development. Incremental, but directionally significant for the aging-cancer interface.
